OncoMatch/Brain Cancer — Glioblastoma (GBM)/MGMT promoter methylation
Brain Cancer — Glioblastoma (GBM)MGMT promoter methylation Clinical Trials
MGMT promoter methylation, found in approximately 40–45% of GBM, silences the DNA repair enzyme MGMT and predicts benefit from temozolomide alkylating chemotherapy — the backbone of standard chemoradiation. MGMT-unmethylated GBM has poor response to temozolomide and is the primary population for trials of alternative regimens. Trials investigate temozolomide alternatives, MGMT-independent sensitizers, and combination strategies specifically in MGMT-unmethylated and MGMT-methylated GBM strata.
Top recruiting MGMT promoter methylation Brain Cancer — Glioblastoma (GBM) trials
Ranked by phase and US site count.
See all trials matched to your profile →Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma
Severance Hospital
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Patrick Wen, MD
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
University of California, San Francisco
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Black Diamond Therapeutics, Inc.
WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Northwestern University
G-CSF After Chemo-radiation in Patients With Glioblastoma
Massachusetts General Hospital